VITEK^® REVEAL™

VITEK^® REVEAL™: THE NEW ADDITION TO THE BIOMÉRIEUX SEPSIS SOLUTION

Sepsis management

Predicting antimicrobial resistance (AMR), can be more complex and time-intensive for patients with Gram negative infections.

Early diagnosis and appropriate treatment make a critical difference when it comes to improving sepsis patient outcomes. Hourly delays in antibiotic administration were associated with increased odds of hospital mortality even among patients who received antibiotics within 6 hours.²

The bioMérieux comprehensive Sepsis Solution, with the addition VITEK^® REVEAL™, helps to manage your patient therapy all along the pathway bringing you rapid and reliable results to support clinical decisions for better patient care.

Rapid & accurate results direct from blood culture

VITEK^® REVEAL™ utilizes Small Molecule Sensors that detects the volatiles released by microorganisms as they grow to quantify antibiotic efficacy. Sensor color changes report growth monitored every 10 minutes, allowing the rapid phenotypic identification of growth or its absence and the associated Minimum Inhibitory Concentration (MIC) determination to be made.

• Real-time monitoring of MIC results
• Up to 176 bug drug combinations
• Allows faster antimicrobial therapy de-escalation to support antimicrobial stewardship

Easily integrated within your lab

Adding VITEK^® REVEAL™ to your bioMérieux Sepsis Solution offers you the fastest route to fully actionable results that can support therapy decisions for improved patient outcomes.

• Flexible solution with a modular design to fit any lab
• Access to bioMérieux’s services from consultancy to installation
• Fully integrated sepsis solution from blood culture (BACT/ALERT^® VIRTUO^®), to identification (BIOFIRE^® BCID 2 Panel & VITEK^® MS  PRIME), AST (VITEK^® 2 & VITEK^® REVEAL™) and data analysis (MAESTRIA™)

Make an antimicrobial stewardship impact

bioMérieux has made the fight against antimicrobial resistance one of our core priorities throughout more than 55 years of commitment to serving global public health. Building on our leadership position in microbiology, we provide you with a complete microbiology solution designed to increase your workflow efficiency from sample preparation to result interpretation.

¹Clinical evaluation of the SPECIFIC REVEAL™/VITEK^® REVEAL™ with Gram-negative bacteremia samples in 6 hospitals in France and England - 2021

²Liu VX et al. Am J Respir Crit Care Med. 2017. Vol 196,(7): 856–863

INSTRUMENT

SEALER

SOFTWARE

Resources

Rajeev L, Khomtchouk K, Singh P, Rhodes PA. Detection of carbapenem resistance by the Reveal rapid phenotypic AST assay in strains from the CDC and FDA antimicrobial resistant isolate bank. Poster presented at: ASM Microbe; 2021 June; Anaheim, CA. (PDF)

D Fournier, J Couchot, M Bour, L Rajeev, P Rhodes, P Singh, K Jeannot and P Plésiat. Assessment of the SPECIFIC REVEAL® Rapid AST System in the determination of the sensitivity of Pseudomonas aeruginosa to antibiotics. Poster presented at: 41ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse (RICAI); 2021 December; Paris, France. (PDF)

Rottman M, Rhodes PA, Singh P, Herrmann JL, Jeannot K, Cattoir V, Carbonnelle E, Plesiat P, Williams A, Dortet L. Clinical evaluation of the SPECIFIC REVEAL™ Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England. Poster presented at: 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); 2022 May; Lisbon, Portugal. (PDF)

Tibbetts R, George S, Burwell R, Rajeev L, Rhodes RA, Singh P, Samuel L. Performance of the Reveal Rapid Antibiotic Susceptibility Testing System on Gram-Negative Blood Cultures at a Large Urban Hospital. Journal of Clinical Microbiology; 2022 May.